Aardvark Therapeutics, Inc. Common Stock (AARD) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 22.46M | 18.7M | 17.7M | 15.85M | 10.47M | 9.45M | 5.09M | 6.07M | 2.17M | 2.23M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 5.9M | 4.41M | 3.97M | 2.7M | 2.71M | 1.39M | 1.03M | 2.03M | 861K | 525K |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 16.57M | 14.3M | 13.74M | 13.14M | 7.75M | 8.06M | 4.07M | 4.03M | 1.21M | 1.54M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14K | 103K | 171K |
| Operating Income | -22.46M | -18.7M | -17.7M | -15.85M | -10.47M | -9.45M | -5.09M | -6.07M | -2.17M | -2.23M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -114.56% | -97.93% | -247.73% | -160.96% | -382.27% | -323.2% | - | - | - | - |
| EBITDA | -22.45M | -18.69M | -17.69M | -15.84M | -10.46M | -9.45M | -5.08M | -6.08M | -2.17M | -2.21M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -114.55% | -97.82% | -248.08% | -160.69% | -382.48% | -327.99% | - | - | - | - |
| D&A (Non-Cash Add-back) | 11K | 10K | 10K | 11K | 5K | 0 | 8K | -2K | 2K | 25K |
| EBIT | -22.46M | -18.7M | -17.7M | -15.85M | -10.47M | -9.45M | -5.09M | -6.06M | -2.17M | -2.06M |
| Net Interest Income | 889K | 1.13M | 1.35M | 1.49M | 1.18M | 717K | 1M | 594K | 103K | 118K |
| Interest Income | 889K | 1.13M | 1.35M | 1.49M | 1.18M | 717K | 1M | 594K | 103K | 118K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 876K | 1.11M | 1.39M | 1.48M | 1.16M | 671K | 909K | 624K | -7K | 192K |
| Pretax Income | -21.59M | -17.6M | -16.32M | -14.37M | -9.31M | -8.78M | -4.18M | -5.45M | -2.18M | -2.04M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -21.59M | -17.6M | -16.32M | -14.37M | -9.31M | -8.78M | -4.18M | -5.45M | -2.18M | -2.04M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -131.88% | -100.46% | -290.15% | -163.66% | -327.46% | -330.13% | - | - | - | - |
| Net Income (Continuing) | -21.59M | -17.6M | -16.32M | -14.37M | -9.31M | -8.78M | -4.18M | -5.45M | -2.18M | -2.04M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.99 | -0.81 | -0.75 | -0.66 | -0.43 | -0.40 | -0.20 | -0.25 | -0.10 | -0.10 |
| EPS Growth % | -130.23% | -102.5% | -275% | -164% | -330% | -319.29% | - | - | - | - |
| EPS (Basic) | -0.99 | -0.81 | -0.75 | -0.66 | -0.43 | -0.40 | -0.20 | -0.25 | -0.10 | -0.10 |
| Diluted Shares Outstanding | 21.82M | 21.82M | 21.75M | 21.69M | 21.69M | 21.7M | 21.38M | 21.38M | 21.38M | 21.38M |
| Basic Shares Outstanding | 21.82M | 21.82M | 21.75M | 21.69M | 21.69M | 21.7M | 21.38M | 21.38M | 21.38M | 21.38M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |